Metadichol - a Breakthrough in Diabetes Treatment From Nanorx Inc.

NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Diabetes is generally referred to by doctors as diabetes mellitus, which is a group of metabolic diseases in which the person has high levels of blood glucose (blood sugar) due to low levels of Insulin production by the pancreas or because the body's cells do not respond properly to insulin or both. According to a diabetes.org, diabetes was the seventh leading cause of death in the United States and in many parts of the world. As of today, there is no known cure for diabetes.

Palayakotai R. Raghavan, a renowned scientist has discovered a breakthrough treatment for diabetes with Metadichol®. He is the inventor of Metadichol® and CEO of the company, Nanorx Inc., based in New York, USA. He finished his Ph.D. in organic chemistry from Oregon State University (1979) and completed his MS in chemistry from IIT Mumbai, India. He also got his U.S patents, US 8722093 and US 9006292, for his invention Metadichol®. Dr. Palayakotai R. Raghavan has worked on drug discovery in various companies for more than 25 years.

With his research, he discovered Umbilical Cord Cells Treatment with Metadichol® and its connection with diabetes. IGF (insulin-like growth factor signaling pathway functions in mediating the rapid increase in the number of cells, death of cells, differentiation, survival, metabolism, and migration). Both IGF signaling and insulin require scaffold proteins that are the key regulators of many signaling pathways. These are also called Insulin Receptor Substrate (IRS) proteins that can be used to integrate extracellular signals into intracellular responses, leading to cellular effects.

There are two main IRS proteins present in our human bodies, and they are IRS1 and IRS2. Dr. Palayakotai R. Raghavan has quantified IRS1, IRS2, GLUT4 in Umbilical Cord (UC) cell line by semi-quantitative- PCR. He used β-actin to normalize IRS1, IRS2, GLUT4 gene expression levels. The research is the first example of Umbilical cord cells being induced by a ligand to regulate insulin and glucose levels in our bodies. Metadichol® treatment at different concentrations on Umbilical Cord which resulted in up-regulation of IRS1, IRS2, and GLUT4. According to his study, 100, pg/mL concentrations of Metadichol gave the highest up-regulation of IRS1, IRS2, GLUT4 gene expression levels. Metadichol® besides of TNF alpha inhibitor also inhibits Plasminogen Activation Inhibitor (PAI1) also known as SERPINE1. The above genes play a vital role in diabetes. His results from the experiment correlated with literature data using bioinformatics software. Finally, Metadichol targets multiple genes through multiple signaling pathways thus allowing targeting of numerous diseases that could be the breakthrough of the future of drug discovery.

Media Contact: 
Natalie Paris 
Email: [email protected]

Related Links

US9006292B2

Linkedin

SOURCE Nanorx Inc.